Here we demonstrate a translationally relevant proof of concept that inhibiting ACC1 enhances Treg functional potency and therapeutic efficacy in two different murine models of GVHD, and in mice with xenogeneic GVHD. This evidence concerns the gene ACACA and graft versus host disease.